Home - Products - Polypeptide
Mobile/Wechat/WhatsApp: +852 61915425
Email:niki@healthtide-api.com
CasNo: 116502-52-4
Molecular Formula: C72H128 O48
Chemical Properties |
water solubility 150 g/100 mL |
Description | HCG (Human Chorionic Gonadotropin) 5000 IU (International Units) is a hormone that plays a vital role in reproductive processes, particularly during pregnancy. It is primarily produced by syncytiotrophoblastic cells of the placenta and has several important functions in both men and women. While HCG is primarily associated with pregnancy and fertility, smaller amounts of the hormone are also produced in the pituitary gland, liver, and colon, where it may have additional physiological functions beyond reproductive processes. |
Uses | In women, HCG helps in treating infertility by stimulating ovulation and promoting the development of the egg in the ovary. It also plays a crucial role in maintaining pregnancy by stimulating the corpus luteum to produce progesterone, which is necessary for the maintenance of the uterine lining and the support of the developing fetus. In men, HCG is used to increase sperm count and promote normal sexual development. It can help improve fertility by stimulating the production of testosterone and enhancing sperm production in the testes. |
InChI:InChI=1/C72H128O48/c1-25(73)9-97-17-33-57-41(81)49(89)65(105-33)114-58-34(18-98-10-26(2)74)107-67(51(91)43(58)83)116-60-36(20-100-12-28(4)76)109-69(53(93)45(60)85)118-62-38(22-102-14-30(6)78)111-71(55(95)47(62)87)120-64-40(24-104-16-32(8)80)112-72(56(96)48(64)88)119-63-39(23-103-15-31(7)79)110-70(54(94)46(63)86)117-61-37(21-101-13-29(5)77)108-68(52(92)44(61)84)115-59-35(19-99-11-27(3)75)106-66(113-57)50(90)42(59)82/h25-96H,9-24H2,1-8H3
There are few studies which investigate whether a lower dose of hCG can reduce the incidence of OHSS without adversely effecting the clinical pregnancy (CPR) and implantation rates (IR). This study retrospectively examined outcomes between patients at risk for OHSS who received either 5000 or 10,000 IUs of hCG during ART.
Patients were excluded from the study if they had: PCOS, history of OHSS, or history of previous cancellation due to poor response. Long down-regulation using GnRHa, was confirmed by serum LH levels <2 IU/l and serum E2 <50 pg/ml after which stimulation with hMG was started and continued until one follicle was ≥18 mm and at least 2 other follicles ≥ 16mm with serum E2 level of ± 150 pg/ml per follicle. Two patients were withdrawn from the study before randomization ,1 had OHSS while the other had poor response.